B+
Bull case
20%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
TARA
Protara TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The newly completed THRIVE-3 dose-confirmation enrollment removes one execution step, while three distinct 4Q 2026 clinical or enrollment milestones could improve confidence in the pipeline. Protara reported approximately $162 million of cash, equivalents and investments at June 30 and expected funding into 2028.
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-29.
What can break
ADVANCED-2 enrollment timing and later efficacy or durability may disappoint; enrollment alone is not a clinical readout. [#SEC-8K-2026-08-11]
Momentum
12
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.40 · Bull $4.00 · Bear $1.20Analysis 2026-10-17; returns require an exact persisted reference.
Earnings
2026-10-29
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $25.71
Why
Momentum12 · Δ7d -9.9
Value41 · Δ7d -0.1
Sentiment55 · Δ7d +16.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-29.
- • Sentiment remains the lead driver in the composite, 7D delta +16.5.
Contradictions & invalidation
- • ADVANCED-2 enrollment timing and later efficacy or durability may disappoint; enrollment alone is not a clinical readout. [#SEC-8K-2026-08-11]
- • ADVANCED-3 is being redesigned as an exploratory trial, creating protocol and timing uncertainty. [#SEC-8K-2026-08-11]
- • The October enrollment announcement contains no interim efficacy result.
Catalyst clock
2026-10-29
THRIVE-3 interim dose-confirmation results
Lead driver: Sentiment · See AI snapshot
Momentum
12
8% active weight
Current posture
7d trendSoftening
Δ7d
-9.9
Δ21d
-6.5
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
55
45% active weight
Current posture
7d trendImproving
Δ7d
+16.5
Δ21d
+1.6
Why this grade
Composite grade D. Momentum 11.6 / Value 40.6 / Sentiment 55.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$145.97M
Beta
1.37
Shares Out
59.1M
P/E (TTM) · Derived
-1.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.91
Rev YoY
-100.0%
EPS YoY
+0.4%
Gross Margin
-
Op Margin
-
Net Debt
-$152.2M
Current Ratio
10.97
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data